Verrica Pharmaceuticals (VRCA) announced the appointment of Chris Chapman as its Chief Commercial Officer. Most recently, Chapman served as Chief Commercial Officer at Dermavant Sciences
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan
- YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint
- Verrica announces first patient dosed in program evaluating YCANTH
- Verrica Pharmaceuticals Adds Caligan Partner to Board
- Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline